SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (391)7/26/2005 1:20:17 PM
From: keokalani'nui  Read Replies (3) of 671
 
OK, I read the article. The key advance is the liposomal encapsulation which accounts for the authors' claims. It looks like they have an efficient method to make it (at least for the anti-mouse sRNI-HepB model) and it is given iv and does not seem to induce the IL-x and interferon responses of previous sRNAi delivery efforts. There's some fuzzy stuff in it that I am too dense to perceive and there was some positive control effects (that out of fatigue I will not try to nail down because of the authors' unnecessarily confusing cpd-naming conventions); but compared to the prior month's article out of Harvard where they used an antibody fragment/protamine fusion protein to carry a sRNAi gag sequence into T-cells, Sirna's approach looks like a walk in the park!

Bottom line, I think the development needs to be watched. Maybe rkrw knows something about the owner of the delivery technology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News